Stockscreener 앱 받기
4.25
0.24%
0.010
시장 영업 전:
4.33
0.08
+1.88%
Abcellera Biologics Inc 주식(ABCL)의 최신 뉴스
AbCellera's Q2 2025 Earnings Call: Unpacking Contradictions in Regulatory Focus, Dosing Strategies, and Market Expansion - AInvest
Will AbCellera Biologics Inc. benefit from seasonalityRocket Stock Alert Service - mustnews.co.kr
AbCellera Biologics Advances Clinical Trials and Revenue Growth - TipRanks
AbCellera reports Q2 EPS (12c), consensus (16c) - MSN
AbCellera signals clinical-stage transition with first patient dosing for ABCL635 and targets mid-2026 data milestone - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2025 Earnings Call Transcript - Insider Monkey
AbCellera Biologics 2025 Q2 Earnings Net Loss Narrows Slightly - AInvest
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript - AOL.com
AbCellera Biologics Soars 19.34% on Q2 Revenue Surge - AInvest
AbCellera Biologics Inc. shares rise 15.80% premarket after reporting Q2 revenue beat estimates and beginning Phase 1 clinical trial for ABCL635. - AInvest
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... - Yahoo Finance
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - BioSpace
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
AbCellera Biologics: Promising Pipeline and Strategic Focus Justify Buy Rating - TipRanks
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Canadian biotech firm AbCellera Q2 revenue beats estimates - MarketScreener
AbCellera Biologics Reports Q2 2025 Financial Results - TipRanks
AbCellera soars as revenue more than doubles estimates By Investing.com - Investing.com Australia
Abcellera Biologics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
AbCellera Biologics: A Turning Point in Biotech's Antibody Revolution - AInvest
AbCellera begins dosing in phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria
Earnings Flash (ABCL) AbCellera Biologics Inc. Reports Q2 Revenue $17.1M - MarketScreener
Is AbCellera Biologics Inc. stock overvalued or undervaluedOutstanding yields - Jammu Links News
Is AbCellera Biologics Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News
What are AbCellera Biologics Inc. company’s key revenue driversOver 200% growth - Jammu Links News
What is the risk reward ratio of investing in AbCellera Biologics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
Why is AbCellera Biologics Inc. stock attracting strong analyst attentionMarket-beating returns - Jammu Links News
What is the dividend policy of AbCellera Biologics Inc. stockConsistently superior profits - Jammu Links News
How volatile is AbCellera Biologics Inc. stock compared to the marketBuild a diversified portfolio for risk management - Jammu Links News
How many analysts rate AbCellera Biologics Inc. as a “Buy”Achieve breakthrough financial results - Jammu Links News
How does AbCellera Biologics Inc. generate profit in a changing economySuperior profit margins - Jammu Links News
What drives AbCellera Biologics Inc. stock priceMarket-leading growth rates - Jammu Links News
Does AbCellera Biologics Inc. stock perform well during market downturnsAchieve explosive financial results today - Jammu Links News
Is AbCellera Biologics Inc. a good long term investmentInvest smarter with daily trading signals - Jammu Links News
What analysts say about AbCellera Biologics Inc. stockInvest confidently with professional market insights - Jammu Links News
When is AbCellera Biologics Inc. stock expected to show significant growthAchieve rapid financial growth with smart picks - Jammu Links News
Should I hold or sell AbCellera Biologics Inc. stock in 2025Capitalize on fast-moving trading opportunities - Jammu Links News
What are the latest earnings results for AbCellera Biologics Inc.Beginner Investor Alerts For Fast Growth - Jammu Links News
Piper Sandler Reiterates a Buy Rating on AbCellera Biologics (ABCL) - MSN
AbCellera Biologics Institutional Ownership: Sensitivity to Trading Actions Amid Market Cap Decline - AInvest
Institutional owners may ignore AbCellera Biologics Inc.'s (NASDAQ:ABCL) recent US$125m market cap decline as longer-term profits stay in the green - Yahoo Finance
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Is it the right time to buy AbCellera Biologics Inc. stockAdvanced Screener Report With High Returns - Jammu Links News
What is AbCellera Biologics Inc. company’s growth strategyExpert Picks Guidance For 2025 - Jammu Links News
Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight - GlobeNewswire Inc.
Will AbCellera Biologics Inc. rebound enough to break evenDaily Stock Market Swing Alerts Highlight Key Movers - metal.it
Published on: 2025-07-29 06:49:21 - metal.it
Why AbCellera Biologics Inc. stock attracts strong analyst attentionWeekly Return Pick Forecast Reports Show Trend - metal.it
Why AbCellera Biologics Inc. stock is on top investor watchlistsEntry Plan for Oversold Reversal Stocks Released - beatles.ru
How strong is AbCellera Biologics Inc. company’s balance sheetChart Pattern Trend Scanner With Low Risk - jammulinksnews.com
0.24%
3.39%
자본화:
|
볼륨(24시간):